Effects of different doses of rosuvastatin on lipid metabolism and left ventricular function in patients with type 2 diabetes mellitus accompanied by coronary heart disease
10.3760/cma.j.cn341190-20240809-01022
- VernacularTitle:不同剂量瑞舒伐他汀对T2DM伴冠心病患者脂代谢及左心功能的影响
- Author:
Li ZHANG
1
;
Lihua JIANG
;
Chenghua YIN
Author Information
1. 济南市第二人民医院内科，济南 250001
- Publication Type:Journal Article
- Keywords:
Diabetes mellitus, type 2;
Coronary disease;
Dyslipidemias;
Heart function tests;
Rosuvastatin calcium
- From:
Chinese Journal of Primary Medicine and Pharmacy
2025;32(4):552-556
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the effects of different doses of rosuvastatin on lipid metabolism and left ventricular function in patients with type 2 diabetes mellitus (T2DM) accompanied by coronary heart disease (CHD).Methods:A prospective study was conducted involving 63 patients with T2DM accompanied by CHD who were treated at Jinan 2 nd People's Hospital and The Fifth People's Hospital of Jinan from January 2022 to June 2023. In a randomized case-control study, patients were assigned to either a control group ( n = 31, receiving 10 mg/d of rosuvastatin) or an observation group ( n = 32, receiving 20 mg/d of rosuvastatin) using a random number table method. After 8 weeks of treatment, the therapeutic effects were evaluated, and blood lipid levels and left ventricular function were recorded before and after treatment. Plasma levels of N-terminal pro-B-type natriuretic peptide (NT-proBNP), homocysteine (Hcy), C-reactive protein (CRP), and the distance covered in a 6-minute walk test were compared between the two groups. Patients were followed for 1 year to monitor adverse reactions and the occurrence of adverse cardiovascular events. Results:The effective treatment rate in the observation group was significantly higher than that in the control group [90.63% (29/32) vs. 70.97% (22/31), χ2 = 3.95, P < 0.05). Prior to treatment, there were no statistically significant differences between the two groups regarding blood lipid levels, cardiac ultrasound indicators, serum levels of NT-proBNP, Hcy, and CRP, the distance covered in the 6-minute walk test, and the incidences of adverse reactions and adverse cardiovascular events (all P > 0.05). After treatment, both groups showed a reduction in total cholesterol and low-density lipoprotein cholesterol (both P < 0.05), with the observation group demonstrating significantly lower levels ( t = 10.54, 14.01, both P < 0.001). Additionally, both groups showed an increase in high-density lipoprotein cholesterol ( P < 0.05), but the observation group achieved significantly higher levels ( t = -14.07, P < 0.001). Both groups also exhibited an increase in left ventricular ejection fraction ( P < 0.05), with a greater improvement in the observation group ( t = -2.34, P < 0.05). The left ventricular end-diastolic diameter decreased in both groups ( P < 0.05), but the observation group had a smaller diameter ( t = 2.78, P < 0.05). Levels of NT-proBNP, Hcy, and CRP decreased in both groups (all P < 0.05), with the observation group showing significantly lower levels ( t = 6.55, 3.94, 6.38, all P < 0.001). Finally, the distance covered in the 6-minute walk test increased in both groups ( P < 0.05), with the observation group covering a greater distance ( t = -4.32, P < 0.001). Conclusions:High-dose rosuvastatin can effectively improve lipid metabolism and left ventricular function in patients with T2DM complicated by CHD. It significantly reduces levels of NT-proBNP, Hcy, and CRP, enhances exercise capacity, and demonstrates high safety, indicating a high potential for clinical application.
